ZUO LI YAO YE(SZ:300181)2022-12-08 08:10Group 1: Company Strategy and Management - The company has appointed 3 directors from Zheli Pharmaceutical and 2 from Qinghai Zhu Feng, with the general manager of Zheli serving as the chairman of the formulation company [1] - The strategic cooperation with the formulation company aims to optimize the product structure, enhancing the company's position in the medicinal fungi fermentation pharmaceutical field [2] Group 2: Sales and Marketing Efforts - The company plans to strengthen its marketing efforts, focusing on the integration of the Bai Ling Pian product line, which is expected to enhance the sales of the Wu Ling series through improved team dynamics [2][3] - The company anticipates maintaining a growth rate of over 50% for Bai Ling Pian in the coming years, as it is included in the national medical insurance directory [5] Group 3: Future Investments and Acquisitions - The company will continue to seek opportunities for external growth through acquisitions, particularly in the biopharmaceutical sector and its upstream and downstream supply chains [4] Group 4: Market Challenges and Responses - The slowdown in the growth of Wu Ling capsules is attributed to ongoing medical system reforms and cost control measures affecting the pharmaceutical industry [6] - To ensure stable growth, the company will monitor industry policy changes, enhance marketing strategies, and strengthen its sales team [7]